EVALUATION OF PLATELET PARAMETERS IN CHRONIC KIDNEY DISEASE PATIENTS UNDERGOING HEMODIALYSIS- A TERTIARY CARE CENTRE EXPERIENCE

Main Article Content

Dr. Azka Qazi
Dr. Sabina Khan
Dr. Shivali Sehgal
Dr. Nehal Ahmad
Dr. Anwar Habib

Keywords

Chronic kidney disease (CKD), Hemodialysis, Platelet parameters

Abstract

Background: Chronic Kidney Disease (CKD) is a global issue, with cardiovascular complications as a common cause of mortality in CKD patients on hemodialysis (HD). Platelet indices play major mechanism in pathological processes of vascular thrombosis.


Aim: The aim of the study was to assess platelet parameters including count and platelet indices namely Mean platelet volume (MPV), Platelet large cell ratio (P-LCR), Platelet distribution width (PDW) and Plateletcrit (PCT) in CKD patients undergoing hemodialysis.


Methods: A retrospective evaluation was conducted on the biochemical and hematological parameters accessed from the hospital records of hemodialysis patients who have chronic kidney disease for a period of one year. Platelet indices were obtained using Sysmex-XN 1000 automated six part hematology analyzer. 


Statistical Analysis: The data was entered into Excel spreadsheet (Microsoft, Redmond, Washington) version SPSS 20.0 for data analysis. 


Results: The results showed male predominance (73.33%) with 45 to 65 years age group commonly affected by CKD. The Mean platelet volume, Platelet distribution width and Plateletcrit were found to be elevated in CKD patients in comparison to controls. However only Mean platelet volume and Platelet distribution width were found statistically significant and Platelet counts were lower among the study population.


Conclusion: Early screening of alterations in platelet parameters may prove to be an efficient factor in risk stratification of CKD patients prone to develop venous thromboembolism and cardiovascular diseases.

Abstract 70 | pdf Downloads 27

References

1. Aashitha P M, Chander USK, Muthuvel E. A correlative study of platelet indices in different stages of chronic kidney disease patients in a tertiary care centre. Saudi J PatholMicrobiol. 2021;6(10):375-380.
2. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. Jama. 2007;298(17):2038-47.
3. Levey AS, De Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney international. 2011;80(1):17-28.
4. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. Journal of the American Society of Nephrology. 2005;16(2):489-95.
5. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am SocNephrol. 1999;10:1606-1615.
6. Moeinzadeh F, Shahidi S, Mortazavi M, Dolatkhah S, Kajbaf M, JavanmardSH,et al. Effects of omega-3 fatty acid supplementation on serum biomarkers, inflammatory agents, and quality of life of patients on hemodialysis. Iranian journal of kidney diseases. 2016;10(6):381.
7. Peev V, Nayer A, Contreras G. Dyslipidemia, malnutrition, inflammation, cardiovascular disease and mortality in chronic kidney disease. CurrOpinLipidol. 2014;25(1):54-60.
8. Mitchell RN. Hemodynamic disorders, thromboembolic disease and shock. In: Kumar V, Abbas AK, Fausto N, Aster JC, eds. Robbins and Cotran Pathologic Basis of Disease. 8th ed. New Delhi: Elsevier; 2010:111-134.
9. Abraham G, Varughese S, Thandavan T, Iyengar A, Fernando E, Naqvi SJ, et al. Chronic kidney disease hotspots in developing countries in South Asia. Clinical kidney journal. 2016;9(1):135-41.
10. Schoorl M, Nube M, Bartels P. Platelet depletion, platelet activation and coagulation during treatment with hemodialysis. Scand J Clin Lab Invest. 2011;71(3):240-247
11. Margetic S. Inflammation and haemostasis. Biochem Med (Zagreb). 2012;22:49-62.
12. Verdoia M, Barbieri L, Schaffer A, Bellomo G, Marino P, De Luca G. Impact of renal function on mean platelet volume and its relationship with coronary artery disease: A single-centre cohort study. Thrombosis research. 2016;141:139-44.
13. Bal Z, Bal U, Okyay K, Yilmaz M, Balcioglu S, Turgay O, et al. Hematological parameters can predict the extent of coronary artery disease in patients with end-stage renal disease. International urology and nephrology. 2015;47:1719-25.
14. Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, KonkleB,et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta‐analysis. Journal of Thrombosis and Haemostasis. 2010;8(1):148-56.
15. Ju HY, Kim JK, Hur SM, Woo SA, Park KA, Park MY,et al. Could mean platelet volume be a promising biomarker of progression of chronic kidney disease?. Platelets. 2015;26(2):143-7.
16. Alghythan AK, Alsaeed AH. Hematological changes before and after hemodialysis. Sci Res Essays. 2012;7(4):490-497.
17. Peretti M, Zampieri N, Bertozzi M, Bianchi F, Patanè S, SpigoV,et al. Mean platelet volume and testicular torsion: new findings. Urology Journal. 2019;16(1):83-5.
18. Kim S, Molnar MZ, Fonarow GC, Streja E, Wang J, Gillen DL, et al. Mean platelet volume and mortality risk in a national incident hemodialysis cohort. International journal of cardiology. 2016;220:862-70.
19. Agin M, Kayar Y, Dertli R. The relationship between mean platelet volume and platelet levels of children with Helicobacter pylori and gastritis. PrzGastroenterol. 2019;14(3):198-201.
20. Ay S, Gokdemir B, Sahutoglu S, Sahin S. Relationship between mean platelet volume and malnutrion. Clinical Nutrition. 2018;37:S253.
21. US Renal Data System. USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
22. Ashman N, Macey MG, Fan SL, Azam U, Yaqoob MM. Increased platelet–monocyte aggregates and cardiovascular disease in end-stage renal failure patients. Nephrology Dialysis Transplantation. 2003;18(10):2088-96.
23. Shahbazi M, Ganji KS, Mirzakhani M, Mohammadnia-Afrouzi M, Akbari R. The role of immune response in initiation and progression of chronic kidney disease. Iranian Journal of Kidney Diseases. 2019;13(5):283.
24. Jin K, Vaziri ND. Elevated plasma cyclophillinA in hemodialysis and peritoneal dialysis patients: a novel link to systemic inflammation. Iran J Kidney Dis. 2017;11(1):44-49.
25. Ruggeri ZM, Mendolicchio GL. Adhesion mechanisms in platelet function. Circ Res. 2007;100(12):1673-1685.
26. Brown AS, Hong Y, de Belder A, Beacon H, Beeso J, Sherwood R, et al. Megakaryocyte ploidy and platelet changes in human diabetes and atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17(4):802-7.
27. Osselaer JC, Jamart J, Scheiff JM. Platelet distribution width for differential diagnosis of thrombocytosis. Clin Chem. 1997;43:1072-1076.
28. Koroglu M, Akalin N, Ozkan H, Harmankaya O. Importance of platelet markers for demonstrating the presence of inflammation in the different stages of chronic renal diseases. Eur J Basic Med Sci. 2015;5(1):1-9.
29. Lokesh S, Green SR, Mathew TK, Hemachandar R, Kumar A, Tiwari SR, et al. A comparative study of platelet parameters in end stage renal disease patients undergoing haemodialysis and healthy individuals. Int J Adv Med. 2016;3(3):559-63.